A key focus of the order is improving coordination between the FDA and the Department of Veterans Affairs, allowing faster data sharing and more efficient evaluation of treatments. It also calls for quicker rescheduling of psychedelics once they are approved for medical use, potentially moving them out of restrictive classifications that currently limit research and access.
The president said “in 2024, a study from Stanford University, 30 special operation veterans with traumatic brain injuries underwent — it’s called ibogaine treatment — ibogaine, remember the name,” noting that they “experienced an 80 to 90% reduction in symptoms of depression and anxiety within one month.”
